| Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. | |
| | |
MedLine Citation:
|
PMID: 15337698 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Ischemia/reperfusion (I/R) injury complicates myocardial infarction and stroke by exacerbating tissue damage and increasing risk of mortality. We have recently identified C-type natriuretic peptide (CNP) as an endothelium-derived hyperpolarizing factor in the mesenteric resistance vasculature and described a novel signaling pathway involving activation of natriuretic peptide receptor C (NPR-C), which plays a pivotal role in the regulation of local blood flow. We tested the hypothesis that CNP/NPR-C signaling is a novel regulatory pathway governing coronary blood flow and protecting against I/R injury. METHODS AND RESULTS: CNP and (Cys18)-atrial natriuretic factor (4-23) amide (cANF(4-23)) elicited dose-dependent decreases in coronary perfusion pressure (CPP) that were blocked by Ba(2+) and ouabain in the isolated Langendorff rat heart. The endothelium-dependent vasodilator acetylcholine elicited the release of CNP from the coronary endothelium. CNP and cANF(4-23) reduced infarct size after 25 minutes of global ischemia and 120 minutes of reperfusion, maintaining CPP and left ventricular pressure at preischemic values. The vasorelaxant and protective activity of CNP and cANF(4-23) were enhanced in the absence of endothelium-derived nitric oxide. CONCLUSIONS: Endothelium-derived CNP is involved in the regulation of the coronary circulation, and NPR-C activation underlies the vasorelaxant activity of this peptide. Moreover, this newly defined pathway represents a protective mechanism against I/R injury and a novel target for therapeutic intervention in ischemic cardiovascular disorders. |
| | |
Authors:
|
Adrian Hobbs; Paul Foster; Craig Prescott; Ramona Scotland; Amrita Ahluwalia |
Related Documents
:
|
23129008 - Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricul... 18836068 - A novel and orally active poly(adp-ribose) polymerase inhibitor, kr-33889 [2-[methoxyca... 19787388 - Limb ischemic preconditioning reduces heart and lung injury after an open heart operati... 2959398 - Evidence of myocardial free radical injury during elective repair of tetralogy of fallot. 21700258 - Variability of left ventricular outflow tract gradient during cardiac catheterization i... 2393248 - Malignant hyperthermia. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2004-08-30 |
Journal Detail:
|
Title: Circulation Volume: 110 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2004 Sep |
Date Detail:
|
Created Date: 2004-09-08 Completed Date: 2006-04-07 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 1231-5 Citation Subset: AIM; IM |
Affiliation:
|
Wolfson Institute for Biomedical Research, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetylcholine
/
pharmacology Animals Atrial Natriuretic Factor / pharmacology, therapeutic use Barium / pharmacology Coronary Circulation / drug effects* Drug Evaluation, Preclinical Endothelium, Vascular / drug effects, secretion Male Myocardial Infarction / drug therapy, pathology Myocardial Reperfusion Injury / prevention & control NG-Nitroarginine Methyl Ester / pharmacology Natriuretic Peptide, C-Type / pharmacology, physiology*, secretion, therapeutic use Nitric Oxide / physiology Ouabain / pharmacology Peptide Fragments / pharmacology, therapeutic use Rats Rats, Wistar Receptors, Atrial Natriuretic Factor / drug effects, physiology* Signal Transduction Vasodilation / drug effects Vasodilator Agents / pharmacology, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/(Cys18)-atrial natriuretic factor (4-23)-amide; 0/Peptide Fragments; 0/Vasodilator Agents; 10102-43-9/Nitric Oxide; 127869-51-6/Natriuretic Peptide, C-Type; 50903-99-6/NG-Nitroarginine Methyl Ester; 51-84-3/Acetylcholine; 630-60-4/Ouabain; 7440-39-3/Barium; 85637-73-6/Atrial Natriuretic Factor; EC 4.6.1.2/Receptors, Atrial Natriuretic Factor; EC 4.6.1.2/atrial natriuretic factor receptor C |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions...
Next Document: Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy...